Neurotoxins as Preclinical Models for Parkinson's Disease

被引：8
|
作者：
Segura-Aguilar, Juan [1 ]
机构：
[1] Univ Chile, Dept Mol & Clin Pharmacol, Fac Med, Santiago, Chile
来源：
NEUROTOXICITY RESEARCH | 2018年 / 34卷 / 04期
关键词：
Parkinson's disease; Dopamine; Preclinical models; Neurotoxins; Translational medicine; Clinical studies; Aminochrome; MPTP; 6-Hydroxydopamine; Rotenon; Neurodegeneration; DT-DIAPHORASE PROTECTS; GAMMA AGONIST PIOGLITAZONE; ALPHA-SYNUCLEIN; DOPAMINERGIC-NEURONS; SUBSTANTIA-NIGRA; CELL-LINE; AMINOCHROME TOXICITY; FUNCTIONAL RECOVERY; OXIDATIVE STRESS; MOUSE MODEL;
D O I：
10.1007/s12640-017-9856-0
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Translational medicine is one of the major concerns in this century. While significant advances have been made with scientific knowledge, the translation of their promising results has not led to any new therapies. In Parkinson's disease, a long list of clinical studies, based on preclinical models with exogenous neurotoxins, has failed. Therefore, the aim of this opinion paper is to open discussion about preclinical models for Parkinson's disease based on neurotoxins.
引用
收藏
页码：870 / 877
页数：8
相关论文
共 50 条
  • [41] The relevance of preclinical studies for the treatment of Parkinson's disease
    Gerlach, M
    Foley, P
    Riederer, P
    [J]. JOURNAL OF NEUROLOGY, 2003, 250 (Suppl 1) : 31 - 34
  • [42] Emerging preclinical pharmacological targets for Parkinson's disease
    More, Sandeep Vasant
    Choi, Dong-Kug
    [J]. ONCOTARGET, 2016, 7 (20) : 29835 - 29863
  • [43] Are Sleep Disturbances Preclinical Markers of Parkinson’s Disease?
    Altair B. dos Santos
    Kristi A. Kohlmeier
    George E. Barreto
    [J]. Neurochemical Research, 2015, 40 : 421 - 427
  • [44] Are Sleep Disturbances Preclinical Markers of Parkinson's Disease?
    dos Santos, Altair B.
    Kohlmeier, Kristi A.
    Barreto, George E.
    [J]. NEUROCHEMICAL RESEARCH, 2015, 40 (03) : 421 - 427
  • [45] Development of a new preclinical model of Parkinson’s disease
    Alexandra Le Bras
    [J]. Lab Animal, 2020, 49 : 219 - 219
  • [46] Preclinical diagnosis of parkinson’s disease: Are we there yet?
    Andrew Siderowf
    Matthew B. Stern
    [J]. Current Neurology and Neuroscience Reports, 2006, 6 : 295 - 301
  • [47] Development of a new preclinical model of Parkinson's disease
    Le Bras, Alexandra
    [J]. LAB ANIMAL, 2020, 49 (08) : 219 - 219
  • [48] Preclinical development of gene therapy for Parkinson's disease
    Porras, Gregory
    Bezard, Erwan
    [J]. EXPERIMENTAL NEUROLOGY, 2008, 209 (01) : 72 - 81
  • [49] Targeted Gene Silencing by U1 Adaptor Oligonucleotides in Preclinical Models of Parkinson's Disease and Huntington's Disease
    Richfield, Eric
    Prasad, Kavita
    Brenneman, Mark
    Goraczniak, Rafal
    Gunderson, Samuel
    [J]. MOLECULAR THERAPY, 2016, 24 : S102 - S102
  • [50] Amine-related neurotoxins in Parkinson's disease - Past, present, and future
    Nagatsu, T
    [J]. NEUROTOXICOLOGY AND TERATOLOGY, 2002, 24 (05) : 565 - 569
12345